Proactive Investors - Run By Investors For Investors

Summit Therapeutics shows off potential of Discuva platform at Berlin conference

The presentations are being made at Novel Antimicrobials and AMR Diagnostics 2019, which is being held in Berlin today and tomorrow
bacteria
Many infectious diseases are becoming resistant to current antibiotic treatments

Summit Therapeutics PLC (LON:SUMM) has unveiled two new presentations at an industry conference in Berlin.

The presentations show off the potential of Summit’s Discuva platform, which it is using to identify and develop new antibiotics that infections such as gonorrhoea and staph aren’t resistant to.

READ: Summit’s gonorrhoea antibiotic showing promise

Several programmes of new mechanism antibiotics have emerged from the Discuva Platform, including one targeting gonorrhoea and another targeting ESKAPE pathogens.

Both of those programmes are being discussed at the conference.

“Antimicrobial resistance is a worldwide problem. We need to see scientific innovation to prevent an era of untreatable infections,” said Summit’s president of R&D, David Roblin.

“Through the Discuva Platform, we are using novel science to create targeted, new mechanism antibiotics that are optimised against resistance development.

“Our goal is to develop the most appropriate drug for a specific patient, thereby improving patient outcomes and giving physicians options to address the spread of AMR.”

Summit shares were up 1.6% to 30.5p in early afternoon trading on Thursday.

View full SUMM profile View Profile

Summit Therapeutics PLC Timeline

Related Articles

word cancer under magnifying glass
May 01 2019
The oncology-focused biotech is a mid-clinical-stage therapeutics company.
A doctor's stethoscope and a marijuana plant
February 22 2019
With top-line data from the CONNECT-FX trial on the way, investors are eying the opportunity defined by marijuana-adjacent companies like Zynerba Pharmaceuticals
cancerous cells
April 15 2019
The company’s cancer treatment is based on work undertaken by John Beard, a professor of embryology at Edinburgh University nearly 100 years ago
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use